Stock Yards Bank & Trust Co. Reduces Holdings in Zoetis Inc. $ZTS

Posted by Brenda Bartman on Jul 2nd, 2026

Stock Yards Bank & Trust Co. lessened its position in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 13.5% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 66,813 shares of the company’s stock after selling 10,409 shares during the quarter. Stock Yards Bank & Trust Co.’s holdings in Zoetis were worth $7,898,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the business. Global Wealth Strategies & Associates purchased a new stake in Zoetis in the fourth quarter valued at $25,000. Prosperity Bancshares Inc acquired a new position in shares of Zoetis in the 4th quarter valued at $25,000. Lodestone Wealth Management LLC purchased a new position in shares of Zoetis during the 4th quarter worth $30,000. KERR FINANCIAL PLANNING Corp purchased a new position in shares of Zoetis during the 3rd quarter worth $31,000. Finally, Holos Integrated Wealth LLC acquired a new stake in shares of Zoetis during the 4th quarter worth about $32,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Zoetis news, Director Michael B. Mccallister purchased 3,000 shares of the company’s stock in a transaction on Monday, May 11th. The stock was acquired at an average price of $77.76 per share, for a total transaction of $233,280.00. Following the completion of the purchase, the director directly owned 24,524 shares in the company, valued at approximately $1,906,986.24. The trade was a 13.94% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Paul Bisaro acquired 2,000 shares of the business’s stock in a transaction dated Wednesday, May 13th. The shares were bought at an average cost of $75.88 per share, for a total transaction of $151,760.00. Following the transaction, the director directly owned 27,862 shares of the company’s stock, valued at approximately $2,114,168.56. This trade represents a 7.73% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired a total of 11,650 shares of company stock valued at $886,384 in the last ninety days. Company insiders own 0.22% of the company’s stock.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. Leerink Partners restated a “market perform” rating on shares of Zoetis in a report on Tuesday, March 10th. Citigroup dropped their price target on shares of Zoetis from $145.00 to $112.00 and set a “buy” rating for the company in a research report on Monday, May 18th. JPMorgan Chase & Co. reduced their price target on shares of Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Wall Street Zen lowered shares of Zoetis from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $115.00 price objective on shares of Zoetis in a research report on Friday, May 15th. Seven research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $126.92.

Check Out Our Latest Stock Analysis on Zoetis

Zoetis Price Performance

ZTS opened at $72.48 on Thursday. The stock’s 50-day moving average price is $85.77 and its 200 day moving average price is $109.95. Zoetis Inc. has a 12-month low of $71.47 and a 12-month high of $161.77. The firm has a market cap of $30.39 billion, a price-to-earnings ratio of 12.02, a PEG ratio of 1.12 and a beta of 0.75. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80.

Zoetis (NYSE:ZTS – Get Free Report) last released its earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($0.07). The firm had revenue of $2.26 billion during the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The business’s revenue was up 2.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, sell-side analysts expect that Zoetis Inc. will post 6.87 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be issued a $0.53 dividend. The ex-dividend date is Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.9%. Zoetis’s payout ratio is 35.16%.

Key Headlines Impacting Zoetis

Here are the key news stories impacting Zoetis this week:

Positive Sentiment: One recent note suggested Zoetis’ index shift could reinforce its competitive moat in companion-animal health, which supports the long-term investment case. Zoetis (ZTS) Index Shift: A Harbinger for Its Competitive Moat in Companion-Animal Health?
Neutral Sentiment: Barclays cut its price target on Zoetis to $85 from $136 and kept an equal-weight rating, signaling a more cautious valuation view but not a bearish downgrade. Barclays price target cut on Zoetis
Neutral Sentiment: TD Cowen lowered its target to $104 from $150 while maintaining a buy rating, reflecting softer near-term expectations while still seeing upside from current levels. TD Cowen price target cut on Zoetis
Neutral Sentiment: Multiple firms reminded investors about the July 27 deadline to join the Zoetis securities class action, keeping legal uncertainty in focus for shareholders. Zoetis Inc. (ZTS) Investors: July 27, 2026, Filing Deadline in Securities Fraud Class Action
Neutral Sentiment: Analyst commentary also highlighted that stabilization in Zoetis products may still be several quarters away, which adds to the view that fundamentals could remain challenged in the near term. This analyst thinks stabilization for Zoetis’ products could be several quarters away
Negative Sentiment: The series of class-action notices may raise investor concern about alleged misstatements tied to product adoption, adding a legal overhang to the shares. ZOETIS DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL

Zoetis Profile

(Free Report)

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.